&w=3840&q=100)
Torrent Pharma Q1 results: PAT up 20% on robust sales across territories
The company's revenue from operations rose to ₹3,178 crore in Q1 FY26, reflecting an 11 per cent Y-o-Y growth from ₹2,815 crore in Q1 FY25.
This includes an 11 per cent increase in the company's India revenues, which rose to ₹1,811 crore, led by outperformance in focus therapies.
Torrent's chronic business grew at 13 per cent, compared to the Indian Pharma Market's (IPM's) growth of 9 per cent. The Ahmedabad-based pharma major added that it has 21 brands in the top 500 brands in the IPM, with 14 brands having sales of more than ₹100 crore.
'The figure includes acquisition-related one-off expenses of ₹15 crore,' the company said in a statement.
Apart from the domestic market, the company also saw growth in revenue from foreign markets.
Torrent's revenue from the US market rose by 19 per cent to ₹308 crore, up from ₹259 crore in Q1 FY25.
Similarly, revenues from the Brazil market rose by 11 per cent Y-o-Y in Q1 FY26 to ₹218 crore, up from ₹196 crore in the same period last year. The company attributed this growth to the performance of top brands, new launches, and growth in the generic segment.
On Monday, Torrent's shares rose marginally by 0.75 per cent, ending the day's trade at ₹3,629.50 apiece on the Bombay Stock Exchange.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
17 minutes ago
- Time of India
Subsidy on small-value UPI payments cut, banks look for ways to offset cost
If India's 'free UPI' policy was already pinching banks, the government's latest move has turned the screw further. A fresh cut in incentives for small-value digital payments is prompting banks to quietly shift part of the cost to their partners and customers. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A cut in the government incentive on small-value Unified Payments Interface-based transactions is pushing banks towards levying charges on certain UPI transactions, according to two bankers in the finance ministry reduced the incentive for processing small-value UPI payments at small merchant outlets to 0.15% per transaction from 0.25% last year. The incentive is paid with a lag of 12-18 months, hence the calculation will be based on digital transactions processed in the financial year banks, this reduction is a double whammy of sorts, as it comes on top of the withdrawal of all forms of incentives offered against RuPay debit cards and UPI payments made at large merchant a letter dated March 24 to banks, the finance ministry said it made the decision in consultation with the National Payments Corporation of India, which manages the UPI platform. ET has seen a copy of the finance ministry and NPCI did not respond to emailed questions until press time per regulatory definitions, a small merchant is one with a turnover of less than Rs 20 lakh in the previous fiscal government had introduced the incentive to compensate banks for providing UPI services for free. The decision to cut the subsidy reflects a drastic reduction in the budgetary allocation for digital payments incentive to Rs 1,500 crore in fiscal 2025 from Rs 3,500 crore paid out last year. Bankers said with no government support, they may have to find ways to offset the cost of providing the service.'After the government withdrew the incentive pay-out on a large part of the payments market, now 10 basis points have been reduced on small-value payments as well. Banks will be forced to pass on some of the charges to their payment aggregating partners,' said a senior banker with a private sector bank. The payment aggregators could be passing on these charges to some of the large merchants. ICICI Bank has started passing on some of the charges to its payment partners, news platform the Head and Tale reported on the year prior, the government ran a more elaborate incentive scheme for the digital payments industry, offering 0.25% for payments up to Rs 2,000 across all forms of merchants for UPI and RuPay debit card transactions. Transactions made at government websites for financial service payments like insurance and mutual funds attracted a lower incentive of 0.15% incentive. All those incentives stand withdrawn this ministry's letter to banks said the Department of Financial Services, in consultation with the NPCI and the financial advisor to the government, might revise the charges from time to week, while speaking at an event in Mumbai, Reserve Bank of India governor Sanjay Malhotra spoke about the need to make UPI payments sustainable and mentioned that either the government or the users would have to bear the price of running the payment the digital payments industry has also been pushing the government to bring back the merchant discount rate on UPI payments, the government has said that UPI would continue to operate for to RBI data, the UPI platform had recorded 18.4 billion transactions in June, while RuPay debit card transactions at point-of-sales terminals and ecommerce platforms had totalled 78 million.
Time of India
2 hours ago
- Time of India
Godrej Properties acquires 34 acres land in Vadodara
NEW DELHI: Mumbai-based Godrej Properties (GPL) has acquired 34 acres of land in Vadodara . The development on this land will primarily comprise of plotted residential units and will offer an estimated saleable area of nine lakh sq ft. This marks GPL's second land acquisition in Gujarat in the last one year. Earlier, in October 2024, the company had acquired a three-acre parcel in Vastrapur, Ahmedabad. The company recently acquired a 48-acre land parcel through outright purchase in Doddaballapur, Bengaluru. The development on this land will primarily comprise of plotted units with a development potential of 1.1 million sq ft.
Time of India
2 hours ago
- Time of India
Amid Trump tariff fears, Aurobindo strikes biggest deal; To acquire Lannett for Rs 2185 crore
Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is making its largest acquisition with a 100% stake in Lannett Company from US-based complex generics manufacturer Lannett Seller Holdco Inc for a total enterprise value of $250 million (approx. 2,185 crore) on a cash-free, debt-free basis. The acquisition, to be done through Aurobindo's wholly-owned US subsidiary Aurobindo Pharma USA Inc, will enable the company to expand its manufacturing footprint in the US, Aurobindo Pharma said in a regulatory filing. The Hyderabad-based company said the transaction aligns with its strategic objective to expand its US manufacturing footprint. Lannett has a 4.24 lakh sq ft cGMP (current good manufacturing practices) facility at Seymour in Indiana with a capacity to make around 3.6 billion tablets per annum. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The plant has the capability to manufacture not just tablets but multiple dosage forms, including capsules, liquids, and powders. Aurobindo said Lannett's US-based facility has significant excess capacity and offers potential for further expansion. Lannett's plant has a strong regulatory and DEA (Drug Enforcement Administration) compliance track record and has built strong expertise in non-opioid controlled substances, mainly in ADHD (attention-deficit, hyperactivity disorder) therapeutics, as well as generic liquids. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Gold Is Surging in 2025 — Smart Traders Are Already In IC Markets Learn More Undo Apart from giving a manufacturing facility in the US, the deal will also give Aurobindo access to a complementary portfolio of profitable products as well as a growing contract development and manufacturing organisation business, it added. "The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics in which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo's ability to serve the US generics space and provides strategic diversification into a specialised high-value therapeutic category," Aurobindo Pharma said. The transaction is expected to be completed in 8-12 months and is subject to US Federal Trade Commission approval in addition to other statutory and govt approvals. Though Aurobindo is acquiring Lannett Company Inc, the company will undergo a re-organisation to become Lannett Company LLC before Aurobindo acquires it. Lannett Company clocked a turnover of $306 million (approx. Rs 2674 crore) in the financial year 2024-25. The Lannett acquisition is Aurobindo Pharma's largest buy after its plan to acquire Sandoz's US dermatology and generic oral solids businesses for $1 billion in 2018 fizzled out because they could not secure approval from the US FTC in a timely manner.
